Pharmaceutical

STAT+: Pharmalittle: A ‘King Kong’ of weight-loss drugs...

People who are overweight are flocking to Ozempic to slim down, but looming is L...

STAT+: From a public library whiteboard, a $350 million...

A new biotech VC firm started by veterans of the industry began with talks aroun...

STAT+: The Q2 health tech tracker: 13 key industry even...

STAT has your guide to the must-watch regulatory decisions, clinical trial reado...

Opinion: Millions of people take birth control to treat...

Doctors believe that if they can control the reproductive cycle with synthetic h...

When confronted with mysterious illness in college, ‘Ch...

After trying 20-plus medications, Catherine Ames, 24, is on about a dozen to man...

To build trust among LA’s unhoused, a street medicine t...

For hundreds of unhoused people in Los Angeles, technology offered by a trusted ...

Fewer trips to the dentist? NYU College of Dentistry wi...

A New York University dentistry team won 2023’s STAT Madness competition by deve...

Indian pharma manufacturing: rising investment in Andhr...

Telangana’s pharma manufacturing industry is well established and continues to h...

Alzheimer’s disease not forgotten as FDA oversees recor...

The FDA has seen a record surge in review designations being awarded over the la...

Vertex and CRISPR Therapeutics submit BLAs to FDA for e...

The BLAs are supported by data from ongoing Phase III CLIMB-111 and CLIMB-121 tr...

AGC Biologics and the Jikei University partner for IPF ...

Researchers will focus on identifying the proof of concept and viability to deve...

Panbela Therapeutics and Johns Hopkins to expand ivospe...

The focus will be on expanding the development of investigative agent ivospemin ...

Orbit and Evergreen partner to advance radiopharmaceuti...

The collaboration aims to tap the expanding radiopharmaceuticals industry, which...

Innovations in air filters: How a simple filter solutio...

Energy efficiency has a major impact on a facility’s operational expenditure, bu...

Janssen launches once-daily option for prostate cancer ...

Erleada is the first and only ARI option avaialable as aa once-daily, single-ta...

Adcendo amps up ADC development with €82 million series...

Adcendo plans to use the additional funding to advance its uPARAP-focused ADCs.